06-18 Ensol Biosciences Inc. announced that it has received KRW 4.99999554 billion in funding from Smart & Growth Co., Ltd. CI
06-03 Ensol Biosciences Inc. announced that it expects to receive KRW 4.99999554 billion in funding from Smart & Growth Co., Ltd. CI
30/07/25 Ensol Biosciences Inc. announced that it has received KRW 1.99999305 billion in funding from Capstone Partners Co., Ltd. CI
21/07/25 Ensol Biosciences Inc. announced that it expects to receive KRW 1.99999305 billion in funding from Capstone Partners Co., Ltd. CI
17/07/25 Ensol Biosciences Inc. announced that it has received KRW 20.438726 billion in funding CI
09/07/25 Ensol Biosciences Inc. announced that it expects to receive KRW 20.438726 billion in funding CI
10/06/25 Hyung In-woo entered into a stock purchase agreement to acquire unknown additional stake in Ensol Biosciences Inc. for KRW 14.2 billion. CI
23/01/25 Ensol Biosciences Inc. announced that it has received KRW 9.99999539 billion in funding CI
11/12/24 Ensol Biosciences Inc. announced that it expects to receive KRW 9.99999539 billion in funding CI
13/11/24 Ensol Biosciences Inc. announced that it has received KRW 1.5 billion in funding from Samho Green Investment, Inc. CI
05/11/24 Ensol Biosciences Inc. announced that it expects to receive KRW 1.5 billion in funding from Samho Green Investment, Inc. CI
19/09/24 Ensol Biosciences Inc. announced that it has received KRW 1 billion in funding from MAGNA Investment Co., Ltd. CI
08/09/24 Ensol Biosciences Inc. announced a financing transaction CI
1 day-8.85%
1 week-15.53%
Current month-20.10%
1 month-22.70%
3 months-34.26%
6 months-44.86%
Current year-40.37%
1 week 7,820
Extreme 7820
9,400
1 month 7,820
Extreme 7820
10,930
Current year 7,820
Extreme 7820
17,900
1 year 7,820
Extreme 7820
17,900
3 years 2,800
Extreme 2800
38,800
5 years 2,800
Extreme 2800
38,800
10 years 2,800
Extreme 2800
38,800
Manager TitleAgeSince
Chief Executive Officer 66 19/02/2001
Corporate Officer/Principal 54 27/03/2024
Corporate Officer/Principal 61 26/03/2020
Director TitleAgeSince
Director/Board Member 66 19/02/2001
Director/Board Member 56 -
Director/Board Member 61 26/03/2020
Date Insider Type Main position Quantity % Market Cap. Importance
02/10/25 Buy 3,100 0.0253%
02/10/25 Buy 25,000 0.2041%
02/10/25 Buy 5,500 0.0449%
Change 5-day change 1-year change 3-year change Capi.($)
-8.85%-15.53%-46.73%-13.86% 84.97M
-2.54%+1.31%+54.27%+114.96% 1,135B
-1.42%+3.23%+38.56%+74.44% 635B
+0.16%+0.08%+25.29%+95.23% 505B
-0.31%+3.09%+44.14%+64.80% 378B
-1.34%-0.47%+66.04%+41.00% 358B
-0.68%+2.65%+22.98%+50.39% 295B
-1.20%+3.04%+2.33%+22.86% 266B
-1.79%+1.57%+50.56%+59.08% 237B
-0.73%-0.10%+29.02%+99.67% 193B
Average -1.87%+0.33%+28.65%+60.86% 400.37B
Weighted average by Cap. -1.35%+2.66%+41.02%+79.75%

Financials

2016 2017
Net sales 174M 230B 155M 144M 130M 243M 16.52B 247M 1.73B 684M 8.65B 653M 639M 27.28B 537M 712B 480M 443M 402M 752M 51.02B 764M 5.34B 2.11B 26.73B 2.02B 1.97B 84.28B
Net income -6.07B -8,038B -5.42B -5.01B -4.54B -8.49B -576B -8.63B -60.23B -23.85B -302B -22.77B -22.29B -951B -5.4B -7,159B -4.83B -4.46B -4.04B -7.56B -513B -7.68B -53.64B -21.24B -269B -20.28B -19.85B -847B
Net Debt - -
Logo Ensol Biosciences Inc.
Ensol Biosciences Inc is a Korea-based company primarily engaged in the research and development of pharmaceuticals. The Company is engaged in the research and development of 'Peniel2000' (P2K) for degenerative disc disease, 'P2K' indication expansion, 'Engedi1000' (E1K) for knee osteoarthritis, and anticancer combination therapy. The Company is also engaged in the research and development of canine osteoarthritis therapy, 'Moriah1000' (M1K) for alzheimer’s disease (AD), and 'Hadassah1000' (H1K) for oral obesity treatment. In addition, the Company is engaged in the provision of services such as synthesis and purification services, and consulting on of breeding information systems.
Employees
-
Date Price Change Volume
23/10/26 ₩7,830.00 -8.85% 11,829
22/10/26 ₩8,590.00 -6.32% 5,852
21/10/26 ₩9,170.00 +1.21% 2,616
20/10/26 ₩9,060.00 -3.00% 10,123
19/10/26 ₩9,340.00 +0.76% 1,529
  1. Stock Market
  2. Stocks
  3. A140610 Stock